For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

Percentage of γδ T cells increased in multiple myeloma patients. (A) gating for γδ T cells in multiple myeloma patients; (B) gating for γδ T cells in healthy controls. - Increased CD8⁺ T cells (P < ...

Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, and variability in response, continue to impact therapeutic success.

Colorectal cancer can be treated using immunotherapy approaches that use the immune cells to target cancer cells and induce the killing of those cancer cells. Some colorectal cancer types have been ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

Ben-Gurion University of the Negev's Prof. Alon Monsonego had discovered that T helper lymphocytes, a subset of immune cells which regulate immunity, undergo functional changes with age. These changes ...